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INTRODUCTION
Hypertension occurs in one-third of Western populations and is an important risk factor for stroke, heart failure and hypertensive glomerulosclerosis. There is substantial debate regarding the relative contribution of the kidney, autonomic nervous system, and vascular injury to the development of hypertension. Recently, several experimental studies have implicated aberrant immune activation and inflammation in the pathogenesis of experimental hypertension. [1] [2] [3] It has been suggested that cell death associated with sterile inflammation may lead to an adaptive immune response directed against cell associated antigens. 4 Indeed, in experimental models, T cells are required for a vigorous blood pressure (BP) increase and full pathologic expression of hypertensive injury. 1, 5 Thus, it is important to understand the regulation of the immune response and the precise pathologic contribution of inflammation in hypertensive disease.
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that regulate the immune system. 6 First discovered in murine tumor models, MDSCs are now known to exist in humans and to dramatically increase under various pathologic conditions including graft-versushost disease, inflammatory bowel disease and infection. [7] [8] [9] MDSCs share common features as they all express the myeloid markers CD11b and Gr1, and the ability to suppress T cell activation. 6 MDSCs are generally considered as one of several means by which the immune system limits inflammation and thus prevents excessive inflammatory injury. Perhaps not surprisingly, both excessive accumulation of MDSCs and the insufficient generation of MDSCs have been associated with pathologic processes. 8, 10 Studies examining tumor growth have proposed several mechanisms that direct recruitment and accumulation of MDSCs. However, common features linking MDSC generation in different pathologic conditions are still elusive, except that nonresolving inflammation is a hallmark in all of the conditions. Given the abundant information suggesting that experimental hypertension is associated with chronic immune activation, we examined myeloid cells in hypertension. Here, we report that peripheral CD11b 
RESULTS

Hypertension is associated with increased CD11b
+ Gr1 + cells in the periphery.
We first examined the myeloid populations in an Ang II-induced hypertension model. Mice were administered 980 ng/kg/min of Ang II for 4 weeks. Systolic BP increased and by the end of the first week reached a plateau between 140-150 mmHg ( Figure 1A ). This was associated with a significant increase of circulating CD11b Figure I) . These correspond to granulocytic and monocytic MDSCs found in tumor models. 11 While both populations increased in hypertension, the Gr1 high Ly6C low cells were predominant.
We also examined the myeloid populations in the spleens, kidney and bone marrow (BM) of mice treated with Ang II. At week 3, the percentage of CD11b + Gr1 + cells in the spleens of hypertensive mice increased 2.7-fold compared to normotensive mice ( Figure 1B ). This was despite the fact that the total number of splenocytes remained constant (115.2 ± 9.0 x10 6 for hypertensive mice vs. 118.7 ± 13.6 x10 Ang II has recently been reported to be a chemotactic factor for monocytes and able to mobilize monocytes from the spleen. 12 To exclude the possibility that the accumulated MDSC are specific for Ang II rather than hypertension, we studied two other hypertension models. L-NAME-induced hypertension is mechanistically different from Ang II-induced hypertension in that it is associated with low plasma levels of Ang II. Two cohorts of mice received either 0.5 mg/ml or 1.5 mg/ml L-NAME in drinking water, and their BP and blood CD11b + Gr1 + cell numbers were studied ( Figure 1C) . The group fed a high dose of L-NAME had a more acute BP elevation and reached peak levels about 10 mmHg higher than that of the low dose group. While both groups showed an increase in the number of blood CD11b + Gr1 + cells, the L-NAME high dose group had a faster rise in cell number than the low dose group, corresponding to their BP levels.
We also studied hypertension induced by a high salt diet. 13 In this model, mice were treated with 0.5 mg/ml L-NAME for 4 weeks to induce hypertension and to predispose the animals to salt sensitivity. The L-NAME phase was followed by a 1 week washout period in which both BP and peripheral CD11b + Gr1 + cell numbers fell to normal levels. Beginning on the 6 th week, the animals were fed a high salt diet (4% NaCl) for 3 weeks. In response to the salt load, mice developed hypertension ( Figure 1D ). By the third week of high salt, the rise in BP was associated with more than a 2-fold increase in the number of blood CD11b ), but gradually increased expression of IL-4 receptor α (IL-4Rα) and IFN-γ receptor 1 (IFN-γR1). IL-4Rα is a key component in mediating M2 macrophage differentiation and its expression is associated with MDSCs in tumor models. 14 IFN-γR1 has also been characterized as a feature of MDSCs. Signaling through IFN-γR1 induces the expression of iNOS and has been attributed to the development of MDSCs. 15 Thus, these data show that with the onset of hypertension, splenic CD11b Among the transcription factors involved in myeloid lineage commitment, the CCAAT enhancer binding protein (C/EBP) family plays a fundamental role. A differential expression of C/EBP family members has been associated with specific stages in cell fate determination. 16 C/EBPα is the key factor in driving myeloid differentiation. 17 C/EBPβ is required for emergent granulopoiesis and the formation of MDSCs. 18, 19 C/EBPδ fosters a macrophage pro-inflammatory phenotype. 20 In addition, PU.1 is another fatedetermining transcription factor for myeloid cells, especially macrophages, and its recruitment to inflammatory gene enhancers is required for responses to inflammatory stimuli. 21, 22 We analyzed the expression levels of these transcription factors in splenic CD11b We wished to identify the mechanism MDSCs use to suppress T cells in hypertension. Study of MDSCs in various pathologic models has implicated several different possible agents, such as iNOS, arginase I and ROS. 6, 23, 24 Depending on the model, each of these has been reported to damp host immune responses, either independently or in concert with one another. L-NAME is a pan-NOS inhibitor. When we isolated CD11b + Gr1 + cells from L-NAME-induced hypertensive mice and co-incubated them with T cells, they still showed T cell suppressive effects (Online Figure VA) . Moreover, the iNOS specific inhibitor 1400W did not affect the suppressive activity of the MDSCs from Ang II-treated mice on T cells (Online Figure VB) . These data indicate that iNOS and NO are unlikely to mediate the immunosuppressive effects of hypertensive MDSCs. Finally, using intracellular staining and FCM analysis, we found negligible iNOS expression in the CD11b + Gr1 + cells of hypertensive mice (Online Figure VC) . We also found that there was no significant difference in arginase I expression between CD11b Phagocytic cells use ROS to kill pathogens, and work has suggested that some MDSCs use ROS to suppress T cells. 25, 26 ROS production was measured by the ability of cells to oxidize dehydrorhodamine 123 to the fluorescent cationic rhodamine 123. Splenic MDSCs from mice with either Ang II-or L-NAMEinduced hypertension produced significantly more ROS than equivalent cells from normotensive mice ( Figure 4A, 1) . Also, when MDSCs from hypertensive mice were transferred into normotensive mice, we could detect in vivo by cytofluorogram that they express ROS even after 24 hr (Online Figure VI) , which indicates that the hypertensive MDSCs produce abundant ROS even in a normotensive environment. Unlike other ROS, hydrogen peroxide is long-lived and can easily diffuse between cells. We therefore considered the hypothesis that hydrogen peroxide mediates the suppressive activity of MDSCs. Addition of catalase (which catalyzes the conversion of hydrogen peroxide to water and oxygen) to the immunosuppressive assay, completely eliminated the suppressive activities of MDSCs from either Ang II treated or L-NAME treated mice ( Figure 4B ). These data imply that hydrogen peroxide plays an important role in mediating the suppression of T-cell proliferation by hypertensive MDSCs. Two of the major sources of cellular ROS are mitochondria and cellular NADPH oxidase. 27 We added Ebselen, a potent scavenger of peroxides, to the immunosuppressive assay. The addition of this agent to the hypertensive MDSCs eliminated suppression and resulted in T cell proliferation nearly equivalent to that in an assay performed with CD11b + Gr1 + cells from normotensive mice ( Figure 4C ). We also used mitoEbselen, which specifically localizes to mitochondria and neutralizes mitochondrial produced ROS. mitoEbselen only partially inactivated the suppressive activity of hypertensive MDSCs. Thus, ROS produced by both mitochondria and other cellular compartments plays a major role in the activity of hypertensive MDSCs.
Depletion of MDSCs raises BP in hypertension.
Evidence suggests that inflammation is a critical pathologic process affecting long term BP control. Because MDSCs are potent suppressors of T cells and polarize immunity toward an anti-inflammatory phenotype, we wanted to understand their function in hypertension. To investigate this, we first used a depletion strategy. Gemcitabine has been used extensively to reduce MDSC levels in vivo without substantially altering the numbers of other leukocytes. 28, 29 Mice were injected i.p. with gemcitabine or saline and gemcitabine treatment reduced the number of CD11b Figure 5A ). This difference continued and mice depleted of MDSC had a BP that averaged 16 mmHg higher than the control mice from day 18 until the end of the experiment (P<0.005).
Gemcitabine is a chemotherapeutic agent. To exclude the possibility that the increased BP was due to a mechanism besides MDSC depletion, we next used anti-Gr1 antibody to deplete MDSCs, an approach widely used for MDSC research in tumor models. 29, 30 On day 10 of Ang II infusion, mice received anti-Gr1 antibody i.p. or an equivalent dose of an isotype irrelevant antibody. Another group of mice wer given the same volume of saline. Starting at day 11 and continuing until the end of the experiment, analysis showed a highly significant increase of BP comparing the mice treated with anti-Gr1 antibody vs. the mice treated with control antibody or saline ( Figure 5B , P<0.005). Further, we also measured proteinuria and heart weight at the end of the experiment. Hypertension caused proteinuria and increased heart weight; MDSC depletion exacerbated these pathological changes ( Figure 5C and 5D). Thus, these studies indicate that MDSCs suppress BP in hypertension and reduce organ damage.
Depletion of MDSC is associated with increased T cell activity.
To understand how MDSCs regulate BP, we examined T cell activation in hypertensive mice. Mice were made hypertensive with either Ang II or L-NAME for 3 weeks and their splenic T cell expression of the pro-inflammatory cytokines IFNγ and TNFα was measured. T cell IL-17 was also measured since IL-17 is thought important in mediating hypertensive responses. The kidney regulates BP by controlling salt and water excretion and by being the source of renin. Renal inflammation is a hallmark of hypertension. 32 Therefore, we analyzed renal inflammation to further assess the role of MDSCs in hypertension. Both Ang II and L-NAME hypertension were accompanied by more than a 2-fold increase in the number of renal CD45 Figure 6C , P<0.05). Again, MDSC depletion led to not only a higher BP, but an aggravation in inflammation as indicated by increased renal T cell infiltration and cytokine expression. We also observed a similar result in gemcitabine treated hypertensive mice (Online Figure VIII) .
Administration of MDSCs from wild-type mice but not NADPH oxidase 2 (Nox2) deficient mice reduced BP in hypertension.
The depletion experiments presented above imply a beneficial role of MDSC accumulation in hypertension. We next designed adoptive transfer experiments to examine whether MDSCs derived from hypertensive mice were functional in regulating BP. A cohort of mice was injected i.v. twice with 2×10 DOI: 10.1161/CIRCRESAHA.115.306539 8 II. As a control, a second cohort was treated identically, except they received splenic CD11b + Gr1 + cells from normotensive mice. A third cohort received only PBS. In this protocol, the first transfer of cells was 1 day before recipients were started on Ang II (490 ng/kg/min). The second transfer was 2 days after the start of Ang II. We used an Ang II dose of 490 ng/kg/min instead of 980 ng/kg/min because we wanted to evaluate possible preventive effects of MDSCs on BP increase and 490 ng/kg/min Ang II is relatively milder in forcing a BP increase. During the period between day 0 and day 9, the BP of the mice receiving hypertensive MDSCs was significantly lower than the other two groups ( Figure 7A , P<0.05 and P<0.005 by two-way ANOVA). There was no difference in the BP response between the mice receiving PBS and those receiving CD11b + Gr1 + cells from normotensive mice, indicating that the transfer of normotensive myeloid cells did not affect BP.
To investigate whether ROS production by MDSCs is a major mechanism retarding hypertension development, we performed a similar protocol as above but using gp91 Two cohorts of mice were administered 5×10 6 MDSCs twice from wild-type BM culture and Nox2 -/-BM culture, respectively ( Figure 7B ). As a control, a third cohort was treated identically, except they received fresh total BM cells which had not been cultured in vitro and contained very few MDSCs. BP of the mice receiving total BM cells increased to above 120 mmHg on day 1 and stayed at that level for the remainder of the experiment. However, the BP of the mice receiving MDSCs from wild-type BM culture never surpassed 120 mmHg until day 8. As such, there was a consistent and highly significant difference of at least 10 mmHg during the first week between these two groups (P<0.005). In contrast to the mice receiving MDSCs from wild-type BM culture, the mice receiving MDSCs from Nox2 -/-BM culture had a sustainable increase of BP from day 1 to day 7 and their average systolic BP reached 133 mmHg on day 7. Thus, the mice receiving Nox2 -/-MDSCs averaged 13.5 mmHg higher BP than the mice receiving wild-type MDSCs in the first week ( Figure 7B , P<0.005). We conclude that ROS production is critical for the function of MDSCs in BP control.
In the third experiment, we investigated whether MDSCs could be used as a treatment for established hypertension. Mice received Ang II for 4 weeks. Beginning on day 7, the hypertensive mice received an i.v. injection of 5×10 6 MDSCs every 7 days. Weekly administration of MDSCs had a highly significant impact on BP, reducing systolic BP at day 27 by 37 mmHg and essentially restoring basal BP levels ( Figure 7C ). Thus, MDSC transfer is efficient in both preventing hypertension development and treating established hypertension.
Finally, to know the whereabouts of the transferred MDSCs, we i.v. transferred MDSCs derived from hypertensive GFP transgenic mice into normotensive and hypertensive mice. Twenty-four hours later, we collected blood, spleen, lung, bone marrow, and kidney and counted the numbers of GFP + MDSCs in these organs (Online Figure IX) . Very few transferred MDSCs were found in the blood of either group, suggesting that the cells distributed to tissues. We examined the lung because it is the first organ the transferred cells encounter. It appeared that there were more transferred cells present in the lung of normotensive mice than those of hypertensive mice. Interestingly, more transferred MDSCs repopulated the spleens of hypertensive mice, which is consistent with a role of MDSC in T cell suppression during hypertension. We also found that there was significantly more transferred MDSCs in the kidneys of hypertensive mice than those of normotensive mice, although the number was a magnitude lower than that in the spleen. Instead, there were more transferred MDSCs populating the bone marrow of normotensive mice, which indicates that without peripheral inflammation, these cells are prone to stay at where hematopoiesis begins. DOI: 10.1161/CIRCRESAHA.115.306539 9
DISCUSSION
Our data indicate a previously unknown role of MDSCs in hypertension. While myeloid cells capable of suppressing immune responses were described, the functional effects of these cells were largely defined in the area of cancer. Models of hypertension commonly elicit a chronic inflammatory response. Our study shows that this systemic inflammation is associated with the migration and accumulation of MDSCs in the spleen. These data indicate that the spleen is a critical place where MDSCs interact with T cells in hypertension. This finding is consistent with a recent paper showing that the release of splenic T cells is important in regulating inflammation and BP in hypertension. 33 Kidney inflammation has been shown as a characteristic of hypertension. We analyzed renal inflammation as a function of MDSC numbers and found that a reduction of MDSCs in hypertension is associated with significantly increased numbers of renal inflammatory cell, including T cells. Further, with MDSC depletion, the T cells in spleen and kidney have an increased pro-inflammatory phenotype. Thus, MDSCs act to counter and limit the inflammation and increase of BP. In hypertension, the actions of MDSCs are advantageous. Several mechanisms are known to limit the immune response. For example, regulatory T cells (Treg) are another type of regulatory cell that limits inflammation. Adoptive transfer of Tregs has been shown to reduce inflammation, tissue injury and BP in Ang II-induced hypertension. 34, 35 Similar benefits were observed in aldosterone induced hypertension. 36 MDSCs have been reported to foster the production of inducible Tregs in tumors. 37 Of note, hypertension decreases the circulating Treg number, possibly due to Ang II-induced Treg apoptosis or skewed CD4 + T cell differentiation. 34, 35 This decrease contrasts to the accumulation of MDSCs in the hypertensive models we studied. Further studies of the number and localization of Treg in hypertension models with low Ang II level may shed light on the relationship of Treg and MDSCs in hypertension. In hypertension, it is granulocytic MDSCs that are most increased. This is the same population that most often predominates in malignancy. Gabrilovich and colleagues recently reported that a large proportion of monocytic MDSCs in tumor-bearing mice can acquire phenotypic, morphologic and functional features of granulocytic MDSCs. 38 This mechanism may also occur in the setting of hypertension. All mice have splenic and peripheral CD11b So far, there is no accepted marker system to predict whether a MDSC will be suppressive without evaluating its suppressive function using in vitro T cell assays. As compared to the CD11b + Gr1 + cells found under basal conditions, our data and others show that these newly formed MDSCs have a distinctive pattern of differentiation markers, transcription factors and effector molecules. 39 MDSC expansion is related to a hematopoietic response to inflammation where growth factors such as GM-CSF and G-CSF signal to the BM to transiently increase cellular output. This ''emergency'' hematopoiesis aids in the destruction and elimination of the insulting entity and is followed by tissue repair and resolution. In nonresolving inflammation, the inciting agent remains and the hematopoietic cycle linked to clearance and resolution becomes dysregulated. Presumably, this increase in the number of immunoregulatory MDSCs is one aspect of a dynamic change in the immune system that is both the cause of and the response to the onset of a chronic hypertensive inflammatory state. We analyzed possible mechanisms by which MDSCs may affect T cells and found that MDSCs associated with hypertension made more ROS. Moreover, the experimental finding that adoptive transfer of wild-type MDSCs but not Nox2 -/-MDSCs limited BP increase in recipient mice further indicates that ROS is a key factor mediating the function of MDSCs in vivo. ROS produced by endothelium and vascular smooth muscle play a major role in hypertension, but have often been assumed to be pathologic. 40 However, ROS production is also a key feature of myeloid derived cells. Clinical studies have investigated antioxidant therapy as an adjunct for the treatment of cardiovascular disease. 41 In such studies, it is worth considering that depletion of myeloid ROS production might exacerbate inflammation and have effects contrary to the hoped for result. + cells in the kidneys of normotensive mice and mice infused with Ang II for 3 weeks. C, Mice were fed with 0.5 mg/ml or 1.5 mg/ml L-NAME in water, their BP and blood CD11b + Gr1 + cell numbers were monitored.
D, Mice were pre-treated with L-NAME for 4 weeks followed by 1 week of normal water. They were then fed with a high-salt diet and their systolic BP and blood CD11b + Gr1 + cell numbers were monitored. *P < 0.05; **P < 0.01; ***P < 0.005. or L-NAME. B and C, The immunosuppressive assay was performed using CD11b + Gr1 + from normotensive or hypertensive mice. In some groups B 100 U/ml catalase, C 100 nM Ebselen or 1 nM mitoEbselen was used for the 3-day assay. **P < 0.01; ***P < 0.005.
Figure 5. Depletion of MDSCs enhanced the hypertensive response.
A, Two groups of mice were made hypertensive by Ang II infusion. On day 10, one group was started on i.p. gemcitabine while the other group received a similar volume of saline. BP was measured on the indicated dates. n=6-15. B, A protocol similar to A, except that one group was started on i.p. anti-Gr1 antibody while the other groups received either control isotype antibody or saline. n=7. Data was analyzed by 2-way ANOVA with posttest. Proteinuria (C) and heart weight (D) were measured on normotensive (black), Ang II treated (gray) and Ang II treated mice with MDSC depletion (white). n=6-11. *P < 0.05; ***P < 0.005. 
Novelty and Significance
What Is Known?
• Hypertension is accompanied by systemic inflammation as evidenced by tissue infiltration of T cells and other blood-born inflammatory cells.
• In experimental animals, T cells make a major contribution to the pathogenesis of hypertension and appear obligatory for blood pressure elevation.
What New Information Does This Article Contribute?
• Hypertension is accompanied by an increase of CD11b + Gr1 + myeloid-derived suppressor cells in the blood, spleen and kidney.
• These hypertension-associated myeloid suppressor cells suppress T cell activity, inflammation and eventually blood pressure by producing hydrogen peroxide.
• These findings highlight an immune balance in hypertension in that a subset of myeloid cells are antiinflammatory and act to oppose the rise of blood pressure.
Chronic inflammation is a characteristic of hypertension and T cells are critical in the genesis and development of hypertension. However, the role of other components of hypertension-associated inflammation, especially the role of myeloid cells, is not well defined. We found that in 3 murine models of hypertension, the rise in blood pressure is associated with an increase of myeloid-derived suppressor cells in the blood and the spleen. These cells, in contrast to other inflammatory cells, are beneficial in blood pressure control in that they suppress T cell activity. While reactive oxygen species are generally assumed to be pathogenic in hypertension, hydrogen peroxide produced by these myeloid suppressor cells is critical in their immunosuppressive function and is advantageous. Depletion of these cells aggravated inflammation and the increase in blood pressure. In contrast, adoptive transfer of myeloid-derived suppressor cells delayed the rise in blood pressure in de novo hypertension and decreased blood pressure in established hypertension. These findings highlight a self-regulatory mechanism in hypertension. Further elucidation of this mechanism might provide a potential pathway in the management of refractory hypertension. 
Supplemental Material Detailed Methods
Mice and hypertension models C57BL/6, OT-I (C57BL/6-Tg(TcraTcrb)1100Mjb/J), Nox2 -/-mice (B6.129S-Cybb tm1Din /J) and RFP mice (B6.Cg-Tg(CAG-mRFP1)1F1Hadj/J) were purchased from Jackson Laboratories. Enhanced green fluorescent protein (eGFP) mice (B6-TgN(β-act-EGFP)osbY01) were generously supplied by Dr Okabe.
1 The OT-I and Nox2 -/-mice were on a C57BL/6 background. The mice used in the experiments were male aged between 8-10 weeks old. Hypertension was induced by s.c. infusion of Ang II (980 ng/kg/min unless otherwise indicated) (Pheonix Pharmaceuticals) via osmotic minipump (Alzet) or by L-NAME treatment (0.5 or 1.5 mg/ml in the drinking water) (Bachem). To induce salt-sensitivity, mice were first exposed to L-NAME (0.5 mg/ml in the drinking water) for 4 weeks followed by a washout period of 1 wk where mice received normal drinking water. Finally, mice were fed a high salt diet (4% NaCl in food) for 3 weeks. All mice were maintained in micro isolator cages, and all experimental protocols were approved by the Institutional Animal Care and Use Committee at Cedars Sinai Medical Center.
Blood pressure measurement
Blood pressure was monitored in conscious mice invasively using radiotelemetry or a computerized non-invasive tailcuff system (Visitech Systems, BP-2000 series II, Apex), as described. 2, 3 For the former, mice were anesthetized with isoflurane, and a catheter connected to a radiotelemetry device (model PA-C10; Data Sciences International) was inserted in the left carotid artery. After a 14-day recovery phase, baseline levels were established before Ang II minipump implantation. Data were collected, stored, and analyzed using Dataquest A.R.T. 4.0 software (DSI). For measuring BP by tailcuff, mice were trained for 5 continuous days before data acquisition. BP was determined by averaging 20 measurements, with tracings manually reviewed to verify proper BP determination.
Antibodies and flow Cytometry (FCM)
The following antibody clones were used: M1/70 (anti-CD11b), RB6-8C5 (anti-Gr1), HK1.4 (antiLy6C), 30-F11 (anti-CD45), 16-10A1 (anti-CD80), AF6-120.1 (anti-I-A b ), mIL4R-M1 (anti-IL-4Rα), 4B12 (anti-CCR7), 2E2 (anti-IFNγR), MR5D3 (anti-mannose receptor), TEK4 (anti-Tie2), 72-1 (anti-CD36), XMG1.2 (anti-IFNγ), TC11-18H10.1 (anti-IL-17A), MP6-XT22 (anti-TNFα), 145-2C11 (anti-CD3), 1M7 (anti-CD44) and BM8 (anti-F4/80). All these antibodies were purchased from either eBioscience, BioLegend or Pharmingen. Polyclonal anti-CCR2 Ab was from Thermo Scientific. 7-amino-actinomycin D (7-AAD) was from BioLegend. For staining intracellular proteins, fixation and permeabilization buffers were purchased from eBioscience. We used rabbit Abs to iNOS, arginase I, C/EBPα, C/EBPβ, C/EBPδ and PU.1. PE-labeled monoclonal anti-iNOS (N-20) was from Santa Cruz Biotechnology, anti-arginase I was from GeneTex, C/EBPβ was from Abcam (clone: E299), and C/EBPα, C/EBPδ and PU.1 were from Cell Signaling Technology. Primary staining using these rabbit Abs was followed by secondary staining with PE-conjugated goat anti-rabbit IgG (SouthernBiotech). The stained samples were analyzed on a Beckman Coulter CyAn ADP and data were analyzed with FlowJo software.
ROS measurement
For measuring oxidative burst, Splenocytes were incubated with 0.1 μg/ml Dihydrorhodamine 123 (Life Technologies) for 60 min at 37°C in HBSS buffer plus 0.1% BSA. The reaction was stopped by moving the cells onto ice. The cells were then stained for CD11b and Gr1 before they were subject to FACS analysis. To measure MDSC ROS production in vivo, MDSCs were purified from the spleen of hypertensive RFP-transgenic mice and transferred i.v. to naïve C57BL/6 mice. Twenty-four hours later, 100 μg Dihydrorhodamine 123 were given i.p. to the recipients. After another hour, mice were anesthetized and transcardially perfused with 4⁰C PBS (50 ml), followed by 4⁰C 1% PFA (100 ml). Spleens were immediately removed and embedded in OCT for cryostat cutting at 10 µm longitudinally. After mounting and slip-covering, spleen sections were examined under the confocal microscope (Leica TCS SP5-X).
MDSC surface defining
For examining MDSCs by FCM, we used anti-CD11b vs. 7-AAD to gate the live myeloid cells and then used anti-Gr1 or anti-Gr1 with anti-Ly6C to analyze MDSCs and their subsets. AntiGr1 Ab (Clone RB6-8C5) reacts with the structurally related murine Ly6G and Ly6C molecules, but has a higher affinity for Ly6G than Ly6C. It can be used to co-immunostain with Ly6C but not with Ly6G. 4, 5 In a preliminary experiment, we co-stained CD11b and Ly6C with either Gr1 or Ly6G for the blood of hypertensive mice. We confirmed that anti-Gr1 and anti-Ly6G antibodies are similar in defining the granulocytic and monocytic MDSCs when co-stained with anti-Ly6C (Online Figure IB) . In this paper, we used CD11b + Gr1 + to label MDSC because it includes both populations.
MDSC collection
To collect CD11b + Gr1 + cells generated in vivo, spleens were minced with scissors and were digested with collagenase IV (Worthington) and DNase I (Sigma-Aldrich) for 40 min at 37ºC. Cells were then passed through 70 μm strainer (BD) and were purified by immunomagnetic separation using biotinylated anti-Gr1 antibody and streptavidin-conjugated MicroBeads with MiniMACS columns (Miltenyi Biotec). The isolated cells were >98% CD11b + . Viability was checked by Trypan blue dye exclusion (>95%). For examining the morphology of MDSCs, Gr1 low Ly6C high and Gr1 high Ly6C low cells were purified through anti-Ly6C selection followed by anti-Gr1 selection according to the manufacturer's instructions (Miltenyi Biotec #130-094-538). Cells were cytospined and stained with Wright-Giemsa. Alternatively, we generated MDSCs from BM culture in vitro. Mice were sacrificed and BM cells were obtained from the femurs and tibias. BM cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 25 ng/ml GM-CSF (Peprotech) and 40 ng/ml IL-6 (Peprotech). 6 The cultures were maintained at 37°C in a 5% CO2-humidified atmosphere and, after 4 days, floating cells were harvested. These were predominantly MDSCs.
Immunosuppressive assay
These cells were added in various amounts to CFSE-labeled 2 × 10 5 naïve OT-I splenocytes in flat-bottomed 96-well plates. The plates were pre-coated with 2.5 μg/ml anti-CD3 (Clone 145-2C11 from SouthernBiotech), and when cells were seeded, 1 μg/ml anti-CD28 was added. In some experiments, the co-cultures were promptly stimulated with 0.4 μM SIINFEKL peptide (AnaSpec) without anti-CD3 pre-coating. Three days later, cells were harvested and T cells were identified by APC-labeled anti-CD4 and anti-CD8 Abs (in the wells following anti-CD3/anti-CD28 stimulation) or APC-labeled anti-CD8 Ab alone (in the wells following SIINFEKL stimulation) with co-staining using 7-AAD and APC-Cy7-labeled anti-CD11b to exclude dead cells and myeloid cells. Cells were then studied by FACS analysis of CFSE profiles. In some experiments, CD11b + Gr1 + cells were pre-treated with 10 μM 1400W (Cayman Chemical), 50 μM nor-NOHA (Cayman Chemical), 100 U/ml catalase (Worthington), 100 nM Ebselen (Enzo Life Sciences) or 1 nM mitoEbselen (Enzo Life Sciences) for 30 min before they were co-incubated with CFSE-labeled splenocytes in the presence of these reagents for 3 d. Proliferation index (PI) was calculated as PI=Log[FI nd /MFI all ]/Log [2] , where MFI al is the median fluorescence intensity of all viable T cells and FI nd is the peak fluorescence intensity of the viable non-divided cells. 7 The PI is a mathematic approximation to the median number of divisions.
In vitro MDSC culture and differentiation
CD11b
+ Gr1 + cells were isolated from the spleens of normotensive mice or mice treated with 3 wk of Ang II. 2 × 10 5 cells were cultured with 10 ng/ml M-CSF (Peprotech), 200 ng/ml Flt3l (Peprotech) or 20 ng/ml GM-CSF in RPMI 1640 supplemented with 10% FBS and 10 mM HEPES. After 3 d, the live cells were counted by Trypan blue dye exclusion and were analyzed by FACS.
MDSC depletion
Ten days after the initiation of a hypertensive stimulus, mice were injected i.p. with 75 μg/g of gemcitabine (APP Pharmaceuticals) in 100 μl of saline twice per week for the first week and once per week thereafter. Control mice were hypertensive animals injected with 100 μl of saline alone. Alternatively, hypertensive mice were treated with anti-Gr1 Ab (Clone RB6-8C5, Bio X Cell) i.p. or the control isotype Ab (Clone LTF-2, Bio X Cell) at a dose of 0.25 mg/mouse in 200 μl PBS every other day. The numbers of circulating MDSC were 0.14 ± 0.03 k/μl (ie 1000s per μl) in gemcitabine-treated mice and 0.09 ± 0.02 k/μl in anti-Gr1 treated mice vs. 1.44 ± 0.11 k/μl in vehicle-treated mice (P<0.001). The percentage of MDSC in the spleen were 0.51 ± 0.09% in gemcitabine-treated mice and 0.4 ± 0.04% in anti-Gr1 treated mice vs. 6.25 ± 0.31% in vehicletreated mice (P<0.001). These data indicate that MDSC depletion was efficient.
Kidney inflammatory cell dissociation and cytokine analysis
Following transcardiac perfusion with sterile heparinized PBS (100 ml, 4C), kidneys were harvested and minced, followed by enzymatic digestion with 1.6 mg/ml collagenase IV (Worthington) and 15 units of DNase I (Sigma) at 37C for 45 min in RPMI1640 containing 10% fetal calf serum. Digested tissues were passed through a 70 μm strainer (BD) and inflammatory cells were enriched using a 36% -72% step Percoll (GE Healthcare) gradient. The cells at the interface of the 36% and 72% Percoll were collected and counted. Cells were then cultured in a 96-well plate for 6 h with brefeldin A (eBioscience). Some cells were stimulated with 100 nM PMA (Sigma) and 2 μM ionomycin (Santa Cruz Biotechnology). After culture, cells were studied by FACS staining.
MDSC transfer
MDSCs were either isolated from spleens of mice treated with Ang II (980 ng/kg/min) for 3 wk or derived from in vitro BM culture with GM-CSF and IL-6 for 4 d. The cells were washed and 2 × 10 6 of splenic MDSCs or 5 × 10 6 BM-derived MDSCs were injected i.v. in 100 μl or 200 μl saline, respectively. The controls were mice injected with either the same number of CD11b + Gr1 + cells derived from normotensive spleens or the same volume of vehicle. For some experiments, 2 × 10 6 CFSE-labeled OT-I CD8 + T cells were co-transferred i.v. with 2 × 10 6 MDSCs derived from normotensive or hypertensive mice. One day later, the recipients were i.p. immunized with 400 μg ovalbumin. After another 2 days, mice were sacrificed and the activation profile of splenic OT-I cells were examined.
Proteinuria
Mice were individually housed in metabolic cages for urine sampling. To avoid urine contamination with food, mice were fed a gelled diet containing all necessary nutrients (Nutragel; Bio-Serv; Frenchtown, NJ; Cat: S4798). Animals had free access to food and water at all times. Urinary protein excretion was measured using the micro BCA method.
Statistics
All data are expressed as the arithmetic means ± SEM. Two-way ANOVA with Bonferroni's post-test was used when analyzing changes in data collected over time. One-way ANOVA and 58.1% Neither iNOS nor arginase I is the major effector mediating MDSC function. A, An immunosuppressive assay was performed by incubating splenocytes from C57BL/6 mice with CD11b + Gr1 + cells from normotensive mice or mice treated with L-NAME for 4 weeks. T cells were stimulated with anti-CD3/anti-CD28 antibodies. B, The immunosuppressive assay was performed similarly to A, except that the hypertensive MDSCs were from Ang II-treated mice. In some groups, 10 μM 1400W was used in the 3-day assay. C iNOS and D arginase I expression in CD11b + Gr1 + cells from normotensive mice and Ang II-treated hypertensive mice was evaluated by FCM. Representative histograms are shown from 4 different experiments. E, The immunosuppressive assay was performed similar to B except that in some groups 50 μM nor-NOHA was used in the 3-day assay. ***P < 0.005. infusion with Ang II or L-NAME in the drinking water. Three weeks later, the spleens were harvested and the splenocytes were incubated with brefeldin A for 6 hours. Some of the cells were stimulated with PMA and ionomycin (P+I) during the 6 hour ex vivo incubation.
Cells were then intracellularly stained for IFNγ, TNFα and IL-17 together with surface staining with CD3, CD4 and CD8 and studied by FCM. n=6-10. *P < 0.05; **P < 0.01; ***P < 0.005. GFP transgenic mice were transferred into normotensive and hypertensive mice. Twentyfour hours later, the GFP + cells in the blood, spleen, lung, bone marrow and kidney were counted. n=4. *P < 0.05; ***P < 0.005. * * * ***
